TETRAX
DEAD

Serial Number

97081506

Owner

SYNERGY IMT, INC.

Attorney

Melissa A. Nowak, Reg. No. 68,088

Filing Date

Oct 19, 2021

Add to watchlist:

No watchlists yet
View on USPTO

TETRAX Trademark

Serial Number: 97081506

TETRAX is a trademark filed by SYNERGY IMT, INC. on October 19, 2021. The trademark is classified under Class 1 (Chemicals), Class 5 (Pharmaceuticals), Class 40 (Treatment & Processing), Class 42 (Computer & Scientific). The application is currently no longer active.

Owner Contact Info

SYNERGY IMT, INC.

6502 113th Avenue NE
Kirkland, WA 980337105

Entity Type: 03

Trademark Details

Filing Date

October 19, 2021

Registration Date

Not Registered

Published for Opposition

April 18, 2023

Goods & Services

custom manufacture of therapeutic drugs, namely, custom manufacture of cell therapies and cancer therapies; Manufacture of pharmaceuticals, pharmaceutical ingredients, vaccines and antibodies for others

pharmaceutical preparations and substances for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders; Pharmaceutical products for the diagnosis, prevention and treatment of cancer; Antibodies being pharmaceutical preparations for the diagnosis, treatment and prevention of cancer, immune response disorders, genetic conditions, infectious diseases and vascular diseases; Vaccines; Pharmaceutical preparations for cell therapy; Preparations of blood extracted from humans or animals which have been adapted for medical or therapeutic purposes

biochemicals, namely, antibody-derived antigen binding molecules and antibody-derived recombinant antigen binding molecules for in vitro scientific or research use

custom design and engineering of antibody-derived antigen binding molecules and antibody-derived recombinant antigen binding molecules; Providing a bioinformatics platform as a service (PAAS) featuring computer software for developing antibody-derived antigen binding molecules and antibody-derived recombinant antigen binding molecules; Custom design and engineering of antibodies; Custom design and engineering of antigens; Antibody engineering; Biochemical research and development; Consulting services in the fields of biotechnology, pharmaceutical research and development and genetic science; Development and establishment of testing specifications and procedures in the field of biotechnology; Research and development in the pharmaceutical and biotechnology fields; Scientific research in the development of new cancer therapies; Scientific research in human and animal cell therapy; Platform as a service (PAAS) featuring computer software platforms for analysis of bioinformatic data

Filing History

ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
Jan 16, 2024 MAB6
ABANDONMENT - NO USE STATEMENT FILED
Jan 15, 2024 ABN6
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Jun 13, 2023 NOAM
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Apr 18, 2023 NPUB
PUBLISHED FOR OPPOSITION
Apr 18, 2023 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Mar 29, 2023 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Mar 13, 2023 CNSA
EXAMINER'S AMENDMENT ENTERED
Mar 8, 2023 XAEC
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Mar 8, 2023 GNEN
EXAMINERS AMENDMENT E-MAILED
Mar 8, 2023 GNEA
EXAMINERS AMENDMENT -WRITTEN
Mar 8, 2023 CNEA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Aug 1, 2022 GNRN
NON-FINAL ACTION E-MAILED
Aug 1, 2022 GNRT
NON-FINAL ACTION WRITTEN
Aug 1, 2022 CNRT
ASSIGNED TO EXAMINER
Jul 26, 2022 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Nov 5, 2021 NWOS
NEW APPLICATION ENTERED
Oct 22, 2021 NWAP